Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jan 13th (reported today) which has an aggregated short interest worth USD17.4bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Anz, Woodside Energy, Northern Star, Bhp, Pexa, Lynas Rare Earth, Champion Iron, Macquarie, Qbe Insurance.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jan 13th (reported today) which has an aggregated short interest worth USD17.4bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Anz, Woodside Energy, Northern Star, Bhp, Pexa, Lynas Rare Earth, Champion Iron, Macquarie, Qbe Insurance.


ASX Short Interest Weekly (Jan 13th): Anz, Woodside, Northern Star, BHP

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jan 6th (reported today) which has an aggregated short interest worth USD16.0bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Anz, Bhp, Yancoal Australia, Brambles.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jan 6th (reported today) which has an aggregated short interest worth USD16.0bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Anz, Bhp, Yancoal Australia, Brambles.


ASX Short Interest Weekly (Jan 6th): ANZ, Bhp, Yancoal Australi, Brambles

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Dec 30th (reported today) which has an aggregated short interest worth USD15.4bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in CAB, Fortescue Metals, Westpac, NAB, CSL, Yancoal, Washington H.Soul, Blackmores, De Grey Mining.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Dec 30th (reported today) which has an aggregated short interest worth USD15.4bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in CAB, Fortescue Metals, Westpac, NAB, CSL, Yancoal, Washington H.Soul, Blackmores, De Grey Mining.


ASX Short Interest Weekly (Dec 30th):CAB, Fortescue Metals, Westpac, NAB, CSL

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Clinuvel Pharmaceuticals / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clinuvel-pharmaceuticals-limited" target="_blank" data-smartkarma-citation="entities:17714:1" rel="noopener">Clinuvel Pharmaceuticals (CUV AU)</a> is recording consistent profitable revenue growth backed by Scenesse. 2023 will be marked by several clinical trial progress and data readouts from the company.</li>
<li>The first readouts of the DNA repair program on xeroderma pigmentosum patients treated with afamelanotide are expected to be available early in the new year.</li>
<li>Clinuvel has started FY23 on a strong note, with Q1 recording highest ever customer receipts. Current cash balance of A$138 million represents sufficient funding for nearly eight quarters.</li>
</ul>



Clinuvel Pharmaceuticals (CUV AU) is recording consistent profitable revenue growth backed by Scenesse. 2023 will be marked by several clinical trial progress and data readouts from the company.
The first readouts of the DNA repair program on xeroderma pigmentosum patients treated with afamelanotide are expected to be available early in the new year.
Clinuvel has started FY23 on a strong note, with Q1 recording highest ever customer receipts. Current cash balance of A$138 million represents sufficient funding for nearly eight quarters.


Clinuvel Pharmaceuticals (CUV AU): Strong Start of FY23; Pipeline Progress Enhances Conviction

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Dec 23rd (reported today) which has an aggregated short interest worth USD14.1bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in CBA, Pilbara Minerals, Fortescue Metals, ANZ, NAB.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Dec 23rd (reported today) which has an aggregated short interest worth USD14.1bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in CBA, Pilbara Minerals, Fortescue Metals, ANZ, NAB.


ASX Short Interest Weekly (Dec 23rd): Short Covering for Banks

Australia

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company. The company focused on developing dermatology pharmaceutical products for a range of UV-related skin disorders. Clinuvel's work aims at preventing the symptoms of diseases related to harmful UV radiation.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clinuvel Pharmaceuticals (CUV AU)

ASX Short Interest Weekly (Jan 13th): Anz, Woodside, Northern Star, BHP

We analyzed ASX short interest report for the past week and highlight short interest changes in Anz, Woodside, Northern Star, Bhp, Pexa, Lynas Rare...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Jan 6th): ANZ, Bhp, Yancoal Australi, Brambles

We analyzed ASX short interest report for the past week and highlight short interest changes in Anz, Bhp, Yancoal Australi, Brambles.

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Dec 30th):CAB, Fortescue Metals, Westpac, NAB, CSL

We analyzed ASX short interest report for the past week and highlight short interest changes in CAB, Fortescue Metals, Westpac, NAB, CSL, Yancoal,...

Ke Yan, CFA, FRM